CY1113693T1 - Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων - Google Patents
Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντωνInfo
- Publication number
- CY1113693T1 CY1113693T1 CY20121100979T CY121100979T CY1113693T1 CY 1113693 T1 CY1113693 T1 CY 1113693T1 CY 20121100979 T CY20121100979 T CY 20121100979T CY 121100979 T CY121100979 T CY 121100979T CY 1113693 T1 CY1113693 T1 CY 1113693T1
- Authority
- CY
- Cyprus
- Prior art keywords
- candida
- als
- protein family
- cell adhesion
- immunogenic
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002458 infectious effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 230000002163 immunogen Effects 0.000 abstract 5
- 230000021164 cell adhesion Effects 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 241000222122 Candida albicans Species 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 2
- 206010007134 Candida infections Diseases 0.000 abstract 2
- 201000003984 candidiasis Diseases 0.000 abstract 2
- 241000222173 Candida parapsilosis Species 0.000 abstract 1
- 241000222178 Candida tropicalis Species 0.000 abstract 1
- 241000235645 Pichia kudriavzevii Species 0.000 abstract 1
- 206010041925 Staphylococcal infections Diseases 0.000 abstract 1
- 241000222126 [Candida] glabrata Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 229940095731 candida albicans Drugs 0.000 abstract 1
- 208000032343 candida glabrata infection Diseases 0.000 abstract 1
- 229940055022 candida parapsilosis Drugs 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000013210 hematogenous Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/327,197 US20070077256A1 (en) | 1999-11-19 | 2006-01-06 | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| EP07709622A EP1982190B1 (en) | 2006-01-06 | 2007-01-05 | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113693T1 true CY1113693T1 (el) | 2016-06-22 |
Family
ID=38256965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100979T CY1113693T1 (el) | 2006-01-06 | 2012-10-18 | Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20070077256A1 (enExample) |
| EP (4) | EP2532360B1 (enExample) |
| JP (3) | JP5692963B2 (enExample) |
| AU (1) | AU2007205065B2 (enExample) |
| CA (2) | CA2636277C (enExample) |
| CY (1) | CY1113693T1 (enExample) |
| DK (1) | DK1982190T3 (enExample) |
| ES (3) | ES2391580T3 (enExample) |
| PT (1) | PT1982190E (enExample) |
| WO (1) | WO2007081896A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541008B2 (en) * | 1999-11-19 | 2013-09-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against candidiasis |
| US20060083750A1 (en) * | 1999-11-19 | 2006-04-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| US20070077256A1 (en) | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| CA2766805A1 (en) * | 2009-07-03 | 2011-01-06 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Hyr1 as a target for active and passive immunization against candida |
| WO2012163533A1 (en) | 2011-06-01 | 2012-12-06 | Eth Zurich | T cell epitope of candida albicans |
| WO2013015831A1 (en) * | 2011-07-22 | 2013-01-31 | Novadigm Therapeutics, Inc. | Methods and compositions for vaccinating against staphylococcus aureus |
| RU2717306C2 (ru) | 2013-03-15 | 2020-03-19 | Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер | Композиции и способы лечения грибковых и бактериальных патогенов |
| JP6566616B2 (ja) * | 2014-08-19 | 2019-08-28 | キヤノン株式会社 | 通信装置、その制御方法、およびプログラム |
| JP7036718B2 (ja) | 2015-11-16 | 2022-03-15 | メドインセルル | 滑膜組織への医薬活性成分の小分割化及び／又は標的化の方法 |
| JP2019507759A (ja) * | 2016-03-09 | 2019-03-22 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット |
| US10308571B2 (en) * | 2017-10-11 | 2019-06-04 | Uop Llc | Process for minimizing benzene, toluene, and a recycle loop in a zero benzene aromatics complex |
| US12324830B2 (en) | 2018-04-10 | 2025-06-10 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Methods of treatment for Candida auris infections |
| EP3552620A1 (en) * | 2018-04-11 | 2019-10-16 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Methods of treatment for candida auris infections |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1133829A (en) | 1978-08-24 | 1982-10-19 | Neil J.L. Gilmour | Pasteurellosis vaccines |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5622939A (en) | 1992-08-21 | 1997-04-22 | Alpha-Beta Technology, Inc. | Glucan preparation |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| WO1995031998A1 (en) | 1994-05-23 | 1995-11-30 | The Research & Development Institute, Inc. | Candida albicans adhesin as a vaccine |
| US5668263A (en) | 1994-12-16 | 1997-09-16 | Smithkline Beecham Corporation | Conserved yeast nucleic acid sequences |
| EP0831897B1 (en) | 1995-06-07 | 2001-03-28 | Pfizer Inc. | In ovo vaccination against coccidiosis |
| CA2255669A1 (en) * | 1996-05-16 | 1997-11-20 | The Texas A & M University System | Collagen binding protein compositions and methods of use |
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| US6703025B1 (en) * | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| US7067138B1 (en) | 1999-11-19 | 2006-06-27 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| US8541008B2 (en) * | 1999-11-19 | 2013-09-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against candidiasis |
| US20060083750A1 (en) * | 1999-11-19 | 2006-04-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| US20070077256A1 (en) * | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| EP1461442B1 (en) | 2001-11-30 | 2017-09-06 | Amgen Fremont Inc. | Transgenic animals bearing human ig lambda light chain genes |
| CA2486618C (en) | 2002-05-21 | 2013-04-09 | Schering-Plough Ltd. | Methods for the in vitro culture of sporozoea sp. and uses thereof |
| US7241613B1 (en) | 2002-06-05 | 2007-07-10 | Oscient Pharmaceuticals Corporation | Identification of Candida cell surface proteins and their uses |
| US7723087B2 (en) * | 2002-11-12 | 2010-05-25 | The Brigham And Women's Hospital, Inc. | Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof |
| KR100785601B1 (ko) | 2003-11-21 | 2007-12-14 | 화이자 프로덕츠 인크. | 백신 아쥬반트로서의 항생제의 용도 |
| WO2005060713A2 (en) * | 2003-12-19 | 2005-07-07 | Inhibitex, Inc. | Method of inhibiting candida-related infections using donor selected or donor stimulated immunoglobulin compositions |
| GB0420466D0 (en) | 2004-09-14 | 2004-10-20 | Cassone Antonio | Anti-glucan antibodies |
| WO2006036817A2 (en) | 2004-09-24 | 2006-04-06 | Microbia, Inc. | Fungal variants and uses thereof |
| CA2489194A1 (en) | 2004-12-03 | 2006-06-03 | Guilhem Janbon | Polypeptides involved in candida biofilm formation and uses thereof |
| WO2007126813A2 (en) | 2006-03-29 | 2007-11-08 | Inhibitex, Inc. | Cross-reactive monoclonal antibodies recognizing als family proteins |
| US7732187B2 (en) | 2006-04-17 | 2010-06-08 | Intervet Inc. | Recombinant attenuated clostridium organisms and vaccine |
| EP2164511A1 (en) | 2007-05-22 | 2010-03-24 | Baylor College Of Medicine | Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations |
| TW201010717A (en) | 2008-05-29 | 2010-03-16 | Intervet Int Bv | Coccidiosis vaccines |
| US20100150942A1 (en) | 2008-12-03 | 2010-06-17 | Cantor Thomas L | Affinity purified human polyclonal antibodies and methods of making and using them |
| HUE036372T2 (hu) | 2009-06-22 | 2018-07-30 | Wyeth Llc | Staphylococcus aureus antigének immunogén készítményei |
| CA2766805A1 (en) | 2009-07-03 | 2011-01-06 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Hyr1 as a target for active and passive immunization against candida |
| WO2012163533A1 (en) | 2011-06-01 | 2012-12-06 | Eth Zurich | T cell epitope of candida albicans |
| WO2013015831A1 (en) | 2011-07-22 | 2013-01-31 | Novadigm Therapeutics, Inc. | Methods and compositions for vaccinating against staphylococcus aureus |
| JP2014527084A (ja) | 2011-09-14 | 2014-10-09 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | Ｈｙｒ１由来組成物およびそれを使用する処置方法 |
| RU2717306C2 (ru) | 2013-03-15 | 2020-03-19 | Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер | Композиции и способы лечения грибковых и бактериальных патогенов |
| US20160030533A1 (en) | 2013-03-15 | 2016-02-04 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Compositions and methods of treating fungal and bacterial pathogens |
| WO2014144024A1 (en) | 2013-03-15 | 2014-09-18 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Hyr1 compositions and methods for treating fungal and bacterial pathogens |
| GB201503812D0 (en) | 2015-03-06 | 2015-04-22 | Univ Aberdeen | Antibody molecules and uses thereof |
| JP2019507759A (ja) | 2016-03-09 | 2019-03-22 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット |
-
2006
- 2006-01-06 US US11/327,197 patent/US20070077256A1/en not_active Abandoned
-
2007
- 2007-01-05 ES ES07709622T patent/ES2391580T3/es active Active
- 2007-01-05 US US12/160,073 patent/US20090297562A1/en not_active Abandoned
- 2007-01-05 EP EP12001586.2A patent/EP2532360B1/en not_active Not-in-force
- 2007-01-05 EP EP07709622A patent/EP1982190B1/en not_active Not-in-force
- 2007-01-05 CA CA2636277A patent/CA2636277C/en not_active Expired - Fee Related
- 2007-01-05 EP EP11008862.2A patent/EP2428800B1/en not_active Not-in-force
- 2007-01-05 AU AU2007205065A patent/AU2007205065B2/en not_active Ceased
- 2007-01-05 DK DK07709622.0T patent/DK1982190T3/da active
- 2007-01-05 CA CA2948424A patent/CA2948424A1/en not_active Abandoned
- 2007-01-05 WO PCT/US2007/000433 patent/WO2007081896A2/en not_active Ceased
- 2007-01-05 ES ES11008862.2T patent/ES2608309T3/es active Active
- 2007-01-05 ES ES12001586.2T patent/ES2608354T3/es active Active
- 2007-01-05 EP EP12001595A patent/EP2532361A1/en not_active Withdrawn
- 2007-01-05 JP JP2008549598A patent/JP5692963B2/ja not_active Expired - Fee Related
- 2007-01-05 PT PT07709622T patent/PT1982190E/pt unknown
-
2011
- 2011-01-10 US US12/987,949 patent/US20120014995A1/en not_active Abandoned
-
2012
- 2012-09-21 JP JP2012207831A patent/JP5775044B2/ja not_active Expired - Fee Related
- 2012-10-18 CY CY20121100979T patent/CY1113693T1/el unknown
-
2013
- 2013-03-05 US US13/785,835 patent/US20140037689A1/en not_active Abandoned
-
2014
- 2014-05-22 JP JP2014105980A patent/JP2014148547A/ja not_active Withdrawn
-
2016
- 2016-02-03 US US15/014,440 patent/US10300120B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014148547A (ja) | 2014-08-21 |
| AU2007205065A1 (en) | 2007-07-19 |
| JP2012255031A (ja) | 2012-12-27 |
| EP1982190B1 (en) | 2012-07-18 |
| WO2007081896A2 (en) | 2007-07-19 |
| EP1982190A2 (en) | 2008-10-22 |
| ES2608354T3 (es) | 2017-04-10 |
| US20090297562A1 (en) | 2009-12-03 |
| ES2391580T3 (es) | 2012-11-28 |
| EP2428800A1 (en) | 2012-03-14 |
| WO2007081896A3 (en) | 2007-11-22 |
| PT1982190E (pt) | 2012-10-22 |
| EP2428800B1 (en) | 2016-09-28 |
| DK1982190T3 (da) | 2012-10-22 |
| JP5692963B2 (ja) | 2015-04-01 |
| US20160220648A1 (en) | 2016-08-04 |
| CA2948424A1 (en) | 2007-07-19 |
| US20070077256A1 (en) | 2007-04-05 |
| ES2608309T3 (es) | 2017-04-07 |
| US10300120B2 (en) | 2019-05-28 |
| US20120014995A1 (en) | 2012-01-19 |
| EP2532360A1 (en) | 2012-12-12 |
| EP2532361A1 (en) | 2012-12-12 |
| AU2007205065B2 (en) | 2013-10-31 |
| JP5775044B2 (ja) | 2015-09-09 |
| EP1982190A4 (en) | 2009-12-23 |
| CA2636277C (en) | 2017-06-13 |
| EP2532360B1 (en) | 2016-09-28 |
| CA2636277A1 (en) | 2007-07-19 |
| US20140037689A1 (en) | 2014-02-06 |
| JP2009524601A (ja) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113693T1 (el) | Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων | |
| JP2010516290A5 (enExample) | ||
| CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| PE20210376A1 (es) | Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer | |
| EA201001212A1 (ru) | Лечение микробных инфекций | |
| DK2719708T3 (da) | Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme | |
| WO2007022425A3 (en) | Influenza recombinant subunit vaccine | |
| SI2280721T1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
| WO2008079372A3 (en) | Novel immunogenic compositions for the prevention and treatment of meningococcal disease | |
| JP2014534202A5 (enExample) | ||
| WO2012058073A3 (en) | Methods and compositions to protect aquatic invertebrates from disease | |
| MX391136B (es) | FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| EA201170493A1 (ru) | Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| WO2008017826A3 (en) | Immunogenic proteins of burkholderia pseudomallei and uses thereof | |
| WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
| DE602007013618D1 (de) | Antikörper gegen das humane cytomegalie-virus (hcmv) | |
| CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
| EA201300132A1 (ru) | Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич | |
| BRPI0513819A (pt) | inibidores de hsp90 | |
| WO2011007359A3 (en) | Antigen specific multi epitope -based anti-infective vaccines | |
| WO2010041241A3 (en) | Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding | |
| Lynn et al. | Immunization of guinea pigs with cement extract induces resistance against Ixodes scapularis ticks |